[Tanvex BioPharma, Inc.] Q1 2026 EPS -1.47 NTD
NQ Score
0/100
N1 Content Completeness
6
AI Summary (NQ-processed)
Tanvex BioPharma reported its Q1 2026 financial results, posting an EPS of -1.47 NTD and a net loss of 389 million NTD on revenues of 133 million NTD.